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Abstract
EBV (Epstein-Barr Virus) and other human DNAviruses are associated with autoimmune syndromes in epidemiologic studies.
In this work, immunoglobulin G response to EBV-encoded proteins which share regions with human immune response proteins
from the human host including ZEBRA (BZLF-1 encoded protein), BALF-2 recombinase expressed primarily during the viral
lytic replication cycle, and EBNA-1 (Epstein-Barr Virus Nuclear Antigen) expressed during the viral latency cycle respectively
were characterized using a laser-printed micro-array (PEPperprint.com). IgG response to conserved BA/T hooks^ in EBV-
encoded proteins such as EBNA-1 and the BALF-2 recombinase related to host DNA-binding proteins including RAG-1
recombinase and histones, and EBV-encoded virokines such as the IL-10 homologue BCRF-1 suggest further directions for
clinical research. The author suggests that proteomic Bmolecular fingerprints^ of the immune response to viral proteins shared
with human immune response genes are potentially useful in early diagnosis and monitoring of autoantibody production and
response to therapy in EBV-related autoimmune syndromes.
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Introduction
DNA viruses such as EBV (Epstein-Barr Virus) have been
associated with numerous autoimmune syndromes in epide-
miologic studies, but the specific role of infection remains
unresolved [1–3]. Conventional serologic testing for EBV is
available using specific immunoglobulin G (IgG) binding to
viral proteins such as EBNA-1 (Epstein-Barr Virus Nuclear
Antigen-1), VCA (Viral Capsid Antigen), and EA (viral com-
ponents termed Early Antigen). A correlation between
antigen-specific IgG levels to specific EBV proteins has been
reported in SLE, MS (multiple sclerosis), and other autoim-
mune syndromes [4–9]. Since the vast majority of the adult
population is positive for EBV, it would be useful to have
additional laboratory analysis for clinical evaluation and mon-
itoring of autoimmune disease in patients based on response to
past EBV infection [10–13].
Recent developments in proteomic analysis and technolo-
gy have dramatically increased the power and lowered the cost
of many immunological tests [14]. Presently, the standard of
diagnosis for many autoimmune diseases is based on ANA
(anti-nuclear antibody) assays in which immunoglobulin
binding is characterized against the cell cytoplasm and nucle-
us and related IgG binding assays. While ANA and immuno-
assay technology can in principle be automated, a more recent
approach is the use of specific antigenic host and viral proteins
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printed in a microarray with sensitivity similar or great than
that of the ANA [15, 16]. Using proteomic technology, hun-
dreds or even thousands of epitopes can be analyzed simulta-
neously with a single serum sample. Detailed mapping of
autoreactive viral epitopes could suggest epitopes capable of
differentiating healthy patients versus patients with autoim-
mune syndromes such as SLE and scleroderma in which
EBV reactivation, EBNA-1, and ZEBRA expression are evi-
dent [17–19].
Viral proteins trigger autoreactive IgG is Bmolecular
mimicry^ in which short regions of similarity between viral
and host proteins are proposed to cross-react and through
Bepitope spreading^ lead to IgG against host proteins in the
presence of viral inflammation and defects in host suppressor
cells [20–24]. EBV-encoded proteins such as ZEBRA (BZLF-
1 protein) share regions with host transcription factors in the
fos/jun family and also to host ankyrin proteins that anchor the
cytoskeleton and regulate host transcription factors such as
p53 and NF-kB important in the immune response [25]. A
well-characterized example of Bmolecular mimicry^ between
EBV and host protein is the similarity between regions of
EBNA-1 and the BSmith Antigen^ in SLE [26, 27]. EBNA-
1 and other proteins including the viral encoded recombinase
BALF-2 protein share a DNA-binding domain termed an A/T
hook with both vertebrate and invertebrate transcription fac-
tors and DNA-binding proteins such as histones and
recombinases [28]. Chronic viruses also encode Bvirokines^
similar to host cytokines [29].
It would therefore be useful to have a sensitive and inex-
pensive method to generate a Bmolecular fingerprint^ of IgG
binding to shared regions of viral and host proteins to compare
between healthy patients with autoimmune disease or at risk in
addition to available more labor intensive and costly technol-
ogy such as the ANA. Using BPEPperprint^ technology, the
authors characterized peptide epitopes that might provide a
sensitive and inexpensive method to generate a proteomic
Bmolecular fingerprint^ of IgG binding to shared regions of
viral and host proteins [30]. Proteomic technology appears to
be highly flexible and inexpensive relative to previous whole
protein-based technologies and also permits localization of
binding to precise intervals of the viral proteins. A limitation
of the technology is that some epitopes which require complex
folding and tertiary interactions of viral proteins or secondary
modifications evident in ELISA binding assays will not be
detected [12, 31]. Conclusions regarding clinical utility there-
fore must await confirmation in additional studies based on
direct comparison with other diagnostic systems [14].
Methods
Molecular images of BA/T hook^ DNA-binding domains in
figures shown were generated by the authors from
published public access coordinates of X-ray crystallogra-
phy coordinates from crystallized RAG-1 nonamer (pdb
file 3GNA) and Herpes Simplex ICP8 (pdb file 1URJ).
The Bpymol^ program was used through license from the
author. Immunoglobulin G response to immunologically
important viral proteins containing regions shared with hu-
man immune response proteins were characterized. Serum
from a healthy EBV-positive donor was obtained with con-
sent for research as part of an ongoing research study of
SLE and scleroderma [32, 33].
Using proprietary technology (PEPerprint.com,
Heidelberg, Germany), overlapping arrays of 15 amino acid
long peptides were synthesized on a microchip [30]. Each
peptide was progressively printed across the region of interest
with 13 amino acid overlap between each peptide or a pro-
gression of two amino acids per peptide. Chips were incubated
with serum, developed, and analyzed with antibodies specific
for immunoglobulin G. Analysis of the immunoglobulin bind-
ing was provided by the chipmanufacturer (PEPperprint.com)
and data was presented using 1 to 100 and 1 to 500 dilutions of
serum. Results are presented for both serum dilutions.
In the figures presented in this work, the results of IgG
binding are presented in two columns to the right of the
printed epitopes, the left column presents the results from
the 1/500 serum dilution and the right column presents the
results from the 1/100 serum dilution to which an arbitrary
factor of B2000^ has been added to assist in graphic anal-
ysis of results. Results shown in this work suggested that
both dilutions of serum gave similar results. Results of IgG
binding to shared epitopes were also determined in a pa-
tient with an EBV-related autoimmune syndrome, sclero-
derma, and were significantly different than the healthy
control, for example elevated IgG response to BZLF-1 as-
sociated epitopes versus EBNA-1 epitopes relative to the
healthy control as might be expected due to increased lytic
viral replication; however, a complete summary of re-
sponses in healthy patients versus autoimmune disease pa-
tients is beyond the scope of this work and will be reported
elsewhere.
In the tables shown in this work, the actual sequence of
each printed peptide is shown with the corresponding location
on the chip to the left of the peptide, followed to the right by
the actual peptide sequence, followed to the right by the
corrected binding intensity donor IgG at 1/500 and 1/100 di-
lutions of serum. In each 15 amino acid sequence, the approx-
imate position of amino acids with maximal IgG detected
binding is underlined. A similar profile or Bfingerprint^ of
response to defined viral peptides could be defined for
patients with EBV-related syndromes as well as syndromes
associated with reactivation of other herpes viruses such as
herpes simplex (an alpha herpes virus latent in neuronal
tissues and CMV) or HHV-6 (beta herpes virus latent in
hematopoietic stem cells).
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Results
IgG response to ZEBRA protein
EBV-encoded ZEBRA protein is a component of the mo-
lecular switch between latency and lytic cycles, and IgG
response to ZEBRA is present in many autoimmune syn-
dromes. For example, a high level of ZEBRA protein ex-
pression is also evident in SLE and scleroderma [32, 33].
As shown in Fig. 1, ZEBRA has a modular structure with
three regions each shared with a different host immune
response protein. The amino terminus of zebra is a tran-
scription activating domain similar to host immune re-
sponse transcription activating domains, the central region
is a DNA-binding domain similar to the fos/jun DNA-
binding proteins that regulate the host immune response,
and the terminal region is related to host anchoring pro-
teins regulating NF-kB and innate immune activation,
resulting in potential antigen sharing with multiple host
DNA-binding proteins including the p53 tumor suppressor
[34, 35].
IgG binding in a healthy EBV-positive donor to the entire
approximately 220 amino acid long ZEBRA amino acid se-
quence was analyzed using a laser-printed peptide chip using
most the laboratory strain B95-8 and a more virulent human
strain of EBV termed BAkata.^ Data are shown for the Akata-
based peptides, similar or identical to those obtained with
B95-8 peptides (B95-8 data not shown). As shown in
Table 1, immunoglobulin G response in a healthy donor was
confined to two epitopes both located in the amino terminal
response of the ZEBRA protein. No immunoglobulin G re-
sponse was evident to the DNA-binding or ZANK (Zebra
ANKyrin-like regions) of zebra in either B95-8 or Akata pro-
tein sequences suggesting that this region of ZEBRA is not the
source of autoantibodies to p53 and related protein in SLE
[36, 37]. Similar IgG binding epitopes in ZEBRA were evi-
dent in a patient with scleroderma as will be discussed in more
detail elsewhere (data not shown). IgG binding regions of
ZEBRA could be used as a part of a molecular fingerprint of
Fig. 1 A schematic diagram of
EBV-encoded ZEBRA switch
protein with IgG-binding peptide
regions shown
Table 1 IgG binding to ZEBRA (BZLF-1) peptides TPDPYQV (aa 15-
21) and PTGSWFP (aa 70–76)
10 6 GMMDPNSTSEDVKFT BZLF1 Akata 0.0 2000.0
10 7 MDPNSTSEDVKFTPD BZLF1 Akata 0.0 2000.0
10 8 PNSTSEDVKFTPDPY BZLF1 Akata 0.0 2000.0
10 9 STSEDVKFTPDPYQV BZLF1 Akata 164.5 2.380.0
10 10 SEDVKFTPDPYQVPF BZLF1 Akata 210.0 2.456.5
10 11 DVKFTPDPYQVPFVQ BZLF1 Akata 68.0 2.167.0
10 12 KFTPDPYQVPFVQAF BZLF1 Akata 45.0 2.072.0
10 13 TPDPYQVPFVQAFDQ BZLF1 Akata 0.0 2000.0
10 14 DPYQVPFVQAFDQAT BZLF1 Akata 0.0 2044.0
10 15 YQVPFVQAFDQATRV BZLF1 Akata 0.0 2000.0
10 34 LPQGQLTAYHVSAAP BZLF1 Akata 0.0 2000.0
10 35 QGQLTAYHVSAAPTG BZLF1 Akata 0.0 2000.0
10 36 QLTAYHVSAAPTGSW BZLF1 Akata 0.0 2000.0
10 37 TAYHVSAAPTGSWFP BZLF1 Akata 15.0 2023.0
10 38 YHVSAAPTGSWFPAP BZLF1 Akata 9.0 2032.0
10 39 VSAAPTGSWFPAPQP BZLF1 Akata 29.5 2074.0
10 40 AAPTGSWFPAPQPAP BZLF1 Akata 61.0 2213.0
10 41 PTGSWFPAPQPAPEN BZLF1 Akata 0.0 2013.0
10 42 GSWFPAPQPAPENAY BZLF1 Akata 0.0 2000.0
10 43 WFPAPQPAPENAYQA BZLF1 Akata 0.0 2017.0
IgG binding to two regions of the highly antigenic ZEBRA protein is
shown. These regions of ZEBRA are identical in the Akata and B-958
EBV strains. IgG binding to (BZLF-1) peptides TPDPYQV (aa 15–21)
was approximately 10 times greater than PTGSWFP (aa 70–76)
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IgG binding to regions of EBV shared with host genes (see
discussion).
IgG response to EBNA-1 peptide regions shared
with host Smith antigen and P53/TRAF binding
domains
EBNA-1 protein is the primary protein expressed during EBV
latency and is highly antigenic for the lifetime of the host due
to periodic viral reactivation and cell lysis releasing small
amounts of EBNA-1 into the circulation [38]. Despite the
nuclear localization of EBNA-1 as suggested by the name
BEpstein-Barr virus nuclear antigen,^ the EBNA-1 generates
a persistent immunoglobulin G response in both healthy pa-
tients and patients with autoimmune syndromes. The unique
role of EBNA-1 in viral latency and persistence has decades of
research on both the humoral and cellular immune response to
EBNA-1 as a tool for viral diagnosis and potentially a tool for
antiviral therapy and vaccines [7, 17, 19]. Because of the
highly repetitive sequences of certain EBNA-1 regions and
the large size of the protein, only specific defined regions of
EBNA-1 were analyzed in this work, in contrast to the entire
amino acid sequence of ZEBRA protein from two different
EBV strains (Table 1).
Research has confirmed that suppressor mechanisms in
healthy patients normally limit Bepitope spreading^ the
similar regions of EBNA-1 and host antigens [26, 27,
39]. Several decades ago, molecular mimicry between
EBNA-1 and the SLE Smith antigen was observed and
subsequently validated in animal models as a mechanism
of viral pathogenesis. To facilitate comparison with
previous studies, the PEPperprint microchip was applied
to a well-characterized EBNA-1 protein epitope similar to
the Smith antigen (Table 2). As shown in Table 3, another
region of EBNA-1 unrelated to the Smith antigen-like re-
gions that binds to host transcription factors P53 and
TRAF also generated a significant host IgG response
[40]. This region of EBNA-1 is not related to ankyrin-
like regions of ZEBRA and is also unlike regions of p53
binding autoantibodies described in SLE and related syn-
dromes [36, 37].
As with the ZEBRA protein regions, specific IgG binding
epitopes of EBNA-1 protein might be a useful diagnostic
marker for characterizing a normal response to EBV infection
and also for identifying defects in immune suppression in a
variety of EBV-related syndromes. Remarkably, a peak of IgG
binding was evident overlapping the EBNA-1 smith antigen-
like sequence, which also co-localizes to a longer peptide:
BPPRRPPPGRRPFFHPVGEADYFEYHQE (EBNA-1 391-
420)^ previously shown by ELISA assay to correlate with
diagnosis of MS [18]. Similar results correlating IgG bind-
ing and also T lymphocyte response progression of MS and
ELISA using EBNA-1 peptide region 400–641 containing
the Smith Ag like region with both T lymphocyte and IgG
binding were reported by another MS case–control study
[7, 17, 19]. If in fact the specific epitope in EBNA-1 cor-
relating with progression in MS is similar or identical to
the EBV associated BSmith antigen^ identified in EBV as
an early antigen in SLE, this observation might suggest
that Bproteomic footprinting^ can identify previously un-
known relationships between pathogenesis and prognosis
of MS and SLE (see BDiscussion^).
Table 2 IgG response was
present to the region of EBNA-1
protein PPPGRRPF (aa 391–398)
corresponding to the Smith
autoantigen PPPGMRPP (shown
highlighted in bold)
EBNA-1 RRPPPGRRPFFHP Smith antigen (PPPGMRPP) region
2 7 PSSQSSSSGSPPRRP EBNA-1 region 1 (smithag) 0.0 2000.0
2 8 SQSSSSGSPPRRPPP EBNA-1 region 1 (smithag) 0.0 2000.0
2 9 SSSSGSPPRRPPPGR EBNA-1 region 1 (smithag) 0.0 2000.0
2 10 SSGSPPRRPPPGRRP EBNA-1 region 1 (smithag) 24.0 2000.0
2 11 GSPPRRPPPGRRPFF EBNA-1 region 1 (smithag) 109.0 2457.0
2 12 PPRRPPPGRRPFFHP EBNA-1 region 1 (smithag) 613.5 3549.0
2 13 RRPPPGRRPFFHPVG EBNA-1 region 1 (smithag) 839.0 4501.5
2 14 PPPGRRPFFHPVGEA EBNA-1 region 1 (smithag) 44.0 2000.0
2 15 PGRRPFFHPVGEADY EBNA-1 region 1 (smithag) 244.0 2976.0
2 16 RRPFFHPVGEADYFE EBNA-1 region 1 (smithagi) 145.0 2713.5
2 17 PFFHPVGEADYFEYH EBNA-1 region 1 (smithagi) 77.5 2345.0
2 18 FHPVGEADYFEYHQE EBNA-1 region 1 (smithagi) 38.0 2227.0
2 19 PVGEADYFEYHQEGG EBNA-1 region 1 (smithagi) 0.0 2000.0
2 20 GEADYFEYHQEGGPD EBNA-1 region 1 (smithagi) 0.0 2015.0
2 21 ADYFEYHQEGGPDGE EBNA-1 region 1 (smithagi) 0.0 2000.0
A region of the EBNA-1 protein is similar to the Smith antigen, an early auto-antigen in some but not all SLE
patients. IgG binding to the EBNA-1 Smith Ag like peptide is approximately three times greater than maximal
binding to ZEBRA epitope TPDPYQV (aa 15–21)
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IgG response to A/T hook region peptides of EBNA-1
shared with viral recombinases and host RAG-1
recombinase
The BA/T hook^ domain is a family of conserved DNA-
binding proteins that bind A/T-rich regions of DNA such as
the immunoglobulin nonamer region (Fig. 2). A/T hook do-
mains are also present in host histone proteins as well as both
vertebrate and invertebrate DNA-binding proteins including
the RAG-1 recombinase [41, 42]. The vertebrate RAG-1 pro-
tein is required for generation of the host immune repertoire
and binds A/T-rich regions of immunoglobulin and T cell
receptor genes with an A/T hook domain shared with a con-
served herpes virus recombinase [43]. Two different amino
terminal EBNA-1 A/T hook regions are required for viral
replication during genome latency probably by linking the
host DNA replication and transcription process to specific
regions of the viral episome [28]. Comparison between the
EBNA-1 A/T hook 1 region of RAG-1, EBNA-1, EBV-
encoded BALF-2, and of other BALF-2 like proteins in herpes
simplex (ICP8) and CMV and EBV (BALF-2) are shown in
Fig. 2. The crystal structure of herpes simplex ICP8 A/T hook
is similar to the RAG-1 A/T hook, although little primary
amino acid homology is evident (Fig. 3).
As shown in Fig. 3, the A/T hook is exposed on the surface
of DNA-binding proteins (published data from host RAG-1
and unpublished data derived from viral ICP8 proteins shown)
and therefore would presumably provoke a strong
Table 3 IgG response was
present to the region of EBNA-1
protein EBNA-1 P53/TRAF-
binding region DVPPGAIE (aa
421–428)
2 31 SGSGSGGGPDGEPDV EBNA-1 region 2 (p53traf) 0.0 2000.0
2 32 SGSGGGPDGEPDVPP EBNA-1 region 2 (p53traf) 0.0 2000.0
2 33 SGGGPDGEPDVPPGA EBNA-1 region 2 (p53traf) 0.0 20,000
2 34 GGPDGEPDVPPGAIE EBNA-1 region 2 (p53traf) 926.5 4538.0
2 35 PDGEPDVPPGAIEQG EBNA-1 region 2 (p53traf) 450.5 3394.5
2 36 GEPDVPPGAIEQGPA EBNA-1 region 2 (p53traf) 171.5 2810.0
2 37 PDVPPGAIEQGPADD EBNA-1 region 2 (p53traf) 314.0 3300.5
2 38 VPPGAIEQGPADDPG EBNA-1 region 2 (p53traf) 9.0 2034.0
2 39 PGAIEQGPADDPGEG EBNA-1 region 2 (p53traf) 0.0 2000.0
2 40 AIEQGPADDPGEGPS EBNA-1 region 2 (p53traf) 0.0 2000.0
IgG binding to the EBNA-1 P5/TRAF binding region peptide is approximately two times greater than maximal
binding to ZEBRA epitope TPDPYQV (aa 15–21)
Fig. 2 Amino acid similarities of A/T hook regions in EBNA-1-1, RAG-
1, and herpes virus recombinases. Top panel: An A/T hook region IgG-
binding epitope in the amino terminus of EBNA-1 protein is similar in
amino acid sequence a conserved region of both the RAG-1 A/T hook
and to widely distributed invertebrate A/T hook proteins hin and
engrailed. Bottom panel: Herpes viruses also contain an A/T hook
(Swiss-Prot accession numbers provided for ICP8 from herpes simplex,
CMV, and EBV BALF-2). Viral A/T hooks are significantly different in
primary amino acid sequence but have a similar antigenic structure and
thus could be useful in quantifying host response both to herpes viruses
and related host proteins such as RAG-1 and histones
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immunoglobulin response if presented to the host immune sys-
tem. As shown in Table 4, a high level of immunoglobulin G
response is present to the first A/T hook region of EBNA-1 and
a significantly lower response to the second hook region of
EBNA-1. The difference in response to these two similar
EBNA-1 structural regions thus specificity is present favoring
recognition of the first EBNA-1 hook region over the second
hook region despite similar protein tertiary structure.
Preliminary data suggests that amuch lower response A/T hook
regions of EBNA-1 is present in a patient with scleroderma
relative to the data shown from a healthy control patient, sug-
gesting that A/T hook regions could be useful to categorize
normal and abnormal response to EBNA-1 (unpublished
observations).
A/T hook regions described could provide a molecular fin-
gerprint for diagnosis and evaluation of autoimmune syn-
dromes as well as a specific marker for previous EBV and
related herpes virus infection. As shown in Table 5, the A/T
hook region of herpes simplex ICP8 protein is highly antigen-
ic in a healthy donor. IgG response to the BALF-2 A/T hook
and host RAG-1 protein was present but at a much decreased
level to the A/T hooks of EBNA-1 or ICP-8 (data not shown).
The authors suggest that in pathologic inflammation, EBNA-1
and related virus A/T hooks could serve as autoantigens, since
the A/T hook is highly immunogenic in EBNA-1 and other
herpes viruses.
IgG response to EBV-encoded Bvirokine^
BCRF-1-encoded protein
Many viral pathogens including EBV encode cytokine
like molecules termed Bvirokines^ and also viral-
encoded cytokine receptors [44–46]. Virokines may also
be reduced or masked as targets of the host immune re-
sponse due to their small size and secondary modifica-
tions such as carboxylation [29]. Virokines could interfere
with host-encoded cytokines through a variety of mecha-
nisms. Preliminary results obtained with a healthy EBV-
positive donor and also a patient with scleroderma, an
EBV-associated autoimmune disease, suggest that most
of the IgG response against virokine IL-10 is a very low
level and restricted primarily to regions of the BCRF-1
protein that are identical to the host IL-10 (data not
shown). These preliminary results are consistent with pre-
vious studies demonstrating that most of the IgG response
to virokines is directed at shared epitopes between
virokine and host cytokine (Fig. 4).
If further studies confirm that virokines such as the
BCL-2-encoded EBV protein are poorly antigenic due to
the extensive sharing of epitopes with host cytokines,
then the host would be vulnerable to the partial agonist
and partial antagonist properties of the EBV-encoded
proteins such as BCRF-1 acting on the IL-10 receptor,
and this could suggest a paradigm for the pathogenic
effects of other shared genes [47–51]. In addition, cur-
rent studies that characterize levels of IL-10 in autoim-
mune syndromes may in fact be measuring a combina-
tion of viral-encoded virokines and host cytokines. The
authors suggest that characterization of IgG response to
virokines, viral-encoded cytokine receptors, and host cy-
tokines such as IL-10 is a novel use of proteomic mo-
lecular fingerprinting that could also help to distinguish
between healthy controls and patients with autoimmune
syndromes.
Fig. 3 A/T hook domain from
host RAG-1 and herpes simplex
virus ICP8. IgG-binding regions
of herpes ICP-8 and
corresponding regions of RAG-1
are shown (box). The human
RAG-1 protein (recombination
activating gene encoded protein)
A/T hook has been crystallized
bound to the A/T-rich nonamer
region of immunoglobulin and T
cell receptor genes, and the
corresponding region of the
herpes simplex ICP-8 protein has
also been crystallized although
not bound to DNA. Very similar
structures are evident in A/T hook
proteins despite divergent amino
acid sequences
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Discussion
Our preliminary results with defined IgG-binding regions of
the ZEBRA, EBNA-1, and virokine BCRF-1 protein in a
healthy donor suggest that proteomic Bmolecular
fingerprinting^ tool significantly lowers the cost and time re-
quired for analysis. Further population-based studies would be
useful to compare between healthy patients with autoimmune
disease or at risk in addition to available more labor-intensive
and costly technology such as the ANA. Proteomic assays
could potentially be used both for diagnosis and also to
monitor response to therapy. In particular, using inexpen-
sive and highly automated Bmolecular fingerprints,^ it
might be possible in the future to identify patients at risk
of autoimmune syndromes prior to development of symp-
toms based solely on their response to specific epitopes in
viral proteins and shared host proteins. Targeting therapy
prior to onset of disease would limit disease progression
and therapy-related adverse events.
Published data from an FDA-approved protein micro-
array showed that levels of IgG response to host proteins
and EBV-encoded EBNA-1 protein and other viral proteins
Table 4 IgG response was
present to EBNA-1 protein A/T
hook region GRPGAPGG (aa
51–57)
4 15 NHGRGRGRGRGRGGG EBNA-1 region 3 (AThook1) 0.0 2000.0
4 16 GRGRGRGRGRGGGRP EBNA-1 region 3 (AThook1) 0.0 2000.0
4 17 GRGRGRGRGGGRPGA EBNA-1 region 3 (AThook1) 0.0 2000.0
4 18 GRGRGRGGGRPGAPG EBNA-1 region 3 (AThook1) 1176.5 6843.0
4 19 GRGRGGGRPGAPGGS EBNA-1 region 3 (AThook1) 300.0 3236.0
4 20 GRGGGRPGAPGGSGS EBNA-1 region 3 (AThook1) 157.0 3064.5
4 21 GGGRPGAPGGSGSGP EBNA-1 region 3 (AThook1) 135.0 2894.0
4 22 GRPGAPGGSGSGPRH EBNA-1 region 3 (AThook1). 386.0 3401.0
4 23 PGAPGGSGSGPRHRD EBNA-1 region 3 (AThook1) 0.0 2149.5
4 24 APGGSGSGPRHRDGV EBNA-1 region 3 (AThook1) 0.0 2000.0
4 25 GGSGSGPRHRDGVRR EBNA-1 region 3 (AThook1) 0.0 2000.0
4 39 SGGGAGAGGAGGAGA EBNA-1 region 4 (AThook2) 0.0 2000.0
4 40 GGAGAGGAGGAGAGG EBNA-1 region 4 (AThook2) 0.0 2000.0
4 41 AGAGGAGGAGAGGGA EBNA-1 region 4 (AThook2) 0.0 2023.0
4 42 AGGAGGAGAGGGAGA EBNA-1 region 4 (AThook2) 28.0 2000.0
4 43 GAGGAGAGGGAGAGG EBNA-1 region 4 (AThook2) 11.0 2018.0
4 44 GGAGAGGGAGAGGAG EBNA-1 region 4 (AThook2) 0.0 2005.0
4 45 AGAGGGAGAGGAGAG EBNA-1 region 4 (AThook2) 5.0 2000.0
4 46 AGGGAGAGGAGAGGG EBNA-1 region 4 (AThook2) 0.0 2000.0
A second A/T hook region of EBNA-1 AGAGGGAG(aa 103–110) also bound IgG at lower levels. Binding to the
EBNA-1 A/T hook peptide GRPGAPGG is approximately 10 times greater than maximal binding to ZEBRA
epitope TPDPYQV (aa 15–21)
Table 5 IgG response to herpes
simplex ICP-8 A/T hook region
EGRPTAPL
24 53 SGVDREGHVVPGFEG RAG1 AT hook region IA-1 0.0 2000.0
24 54 VDREGHVVPGFEGRP RAG1 AT hook region IA-1 0.0 2000.0
24 55 REGHVVPGFEGRPTA RAG1 AT hook region IA-1 0.0 2000.0
24 56 GHVVPGFEGRPTAPL RAG1 AT hook region IA-1 226.0 2865.5
24 57 VVPGFEGRPTAPLVG RAG1 AT hook region IA-1 264.0 2906.5
24 58 PGFEGRPTAPLVGGT RAG1 AT hook region IA-1 27.0 2112.5
24 59 FEGRPTAPLVGGTQE RAG1 AT hook region IA-1 0.0 2028.0
24 60 GRPTAPLVGGTQEFA RAG1 AT hook region IA-1 69.5 2219.5
24 61 PTAPLVGGTQEFAGE RAG1 AT hook region IA-1 6.0 2000.0
24 62 APLVGGTQEFAGEHL RAG1 AT hook region IA-1 0.0 2000.0
24 63 LVGGTQEFAGEHLAM RAG1 AT hook region IA-1 0.0 2000.0
24 64 GGTQEFAGEHLAMLC RAG1 AT hook region IA-1 0.0 2000.0
Binding to the EBNA-1-like peptide GRPGAPGG is less than to EBNA-1 protein A/T hook region GRPGAPGG
and similar to maximal binding to ZEBRA epitope TPDPYQV (aa 15–21)
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could diagnosis both SLE and scleroderma with sensitivity
and specificity similar or greater to conventional ANA test-
ing [15]. Addition of viral protein antigens in this assay
significantly improved the sensitivity and specificity, al-
though the specific IgG-binding epitopes recognized by
immunoglobulin G were not disclosed [15, 16]. In this
work, IgG-binding results are presented derived from a
proprietary laser-printed peptide microchip containing
overlapping peptides from immunologically important
EBV proteins to illustrate the potential of this new
technology.
While abnormal immune response to EBV-specific pro-
teins such as EBNA-1 has been described in autoimmune
syndromes, specific short epitopes described in the work
could facilitate proteomic Bmolecular fingerprints in autoim-
mune disease^ [7, 17–19]. The A/T hook region of EBNA-1
and many herpes virus and host proteins as well as short IgG
binding regions in the lytic ZEBRA switch protein described
in this work also appear to be a promising antigen for
Bmolecular footprints^ of other inflammatory and autoim-
mune syndromes. Viral proteins such as the viral
recombinase BALF-2 protein in Epstein-Barr virus and
its homolog ICP8 in herpes simplex and other alpha, beta,
and gamma Herpesviridae could also provide epitopes de-
fining parameters such as viral reactivation and molecular
mimicry with host proteins [25, 43]. The A/T hook regions
of viral and host proteins are shared between both eukary-
otic and prokaryotic DNA-binding proteins such as the
RAG-1 recombinase and as histones in both vertebrates
and invertebrates including the developmentally regulated
Bhin^ and Bengrailed^ families [41].
Other authors have also recently noted significant overlap
between proteins in the human immune response expressed by
papilloma virus, another DNA virus correlated with SLE and
other human autoimmune syndromes [47–51]. Thus, it seems
that Bgene sharing^ between host immune response genes is
not limited to transcription factors and virokines but may in-
clude all aspects of the host immune response. Preliminary
data obtained from the immune response to some shared
gene-encoded proteins reported in this work suggests that
while some shared gene-encoded proteins such as BZLF-1
and EBNA-1 are highly antigenic and thus trigger IgG against
self-proteins, other EBV-encoded shared genes such as
virokines may be poorly antigenic, permitting the viral-
encoded projects to function as antagonists or partial ago-
nists of the host immune response. The author suggests that
relatively inexpensive new technology such as Bproteomic
fingerprinting^ may be useful to define differences in im-
mune response between patients with autoimmune syn-
dromes and healthy controls including immune response
to Bshared genes.^
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Fig. 4 Virokines and viral-
encoded cytokine receptors as
targets for host IgG response. A
schematic diagram illustrates
several mechanisms through
which host IgG against viral
proteins similar to host cytokines
(virokines) and cytokine receptors
could interfere with endogenous
regulation of suppressor cell
regulatory cytokines such as IL-
10. EBV-encoded IL-10 like
BCRF-1 is approximately 90%
identical to host IL-10 and
preliminary results suggest that
the immune response to BCRF-1-
encoded protein is extremely low
and restricted to areas of
homology to the host IL-10
cytokine (see BDiscussion^)
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